Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells
W Shi, Q Qiu, Z Tong, W Guo, F Zou, Z Feng… - European journal of …, 2020 - Elsevier
Researches on tumor-associated antigen have become a hot target in immunotherapy, but it
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …
Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells.
W Shi, Q Qiu, Z Tong, W Guo, F Zou, Z Feng… - European Journal of …, 2020 - europepmc.org
Researches on tumor-associated antigen have become a hot target in immunotherapy, but it
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …
Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells
W Shi, Q Qiu, Z Tong, W Guo, F Zou… - European journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Researches on tumor-associated antigen have become a hot target in immunotherapy, but it
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …